SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

IPO completed in October 2026 to support the continued development of RTN-001 for uncontrolled and r

RTSN

Related stories